Targeting pancreatic ductal adenocarcinoma acidic microenvironment

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Cruz Monserrate, Zobeida ^a   Roland, Christina L ^a   Deng, Defeng ^a   Arumugam, Thiruvengadam ^a   Moshnikova, Anna ^b   Andreev, Oleg A ^b   Reshetnyak, Yana K ^b   Logsdon, Craig D ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA, PANCREATIC DUCTAL; DIAGNOSTIC IMAGING; DIAGNOSTIC USE; DISEASE MODEL; HUMAN; METABOLISM; MOLECULAR GENETICS; MOUSE; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PERITONEAL NEOPLASMS; PH; PROCEDURES; PROGNOSIS; SECONDARY; SYNTHESIS; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

AMINO ACID SEQUENCE; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PEPTIDES; PERITONEAL NEOPLASMS; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 84897879624     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04410     Document Type: Article

References (37)

1. Siegel, R.,Naishadham,D.&Jemal, A. Cancer statistics, 2012. CA Cancer J Clin 62, 10-29, doi:10.3322/caac.20138 (2012).
2. Yeo, C. J. et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 226, 248-257; discussion 257-260 (1997).
3. Kramer-Marek, G., Gore, J. & Korc, M. Molecular imaging in pancreatic cancer - A roadmap for therapeutic decisions. Cancer Lett 341, 132-138, doi:10.1016/ j.canlet.2013.08.008 (2013).
4. Collisson, E.& Tempero, M. Blinded by the light: molecular imaging in pancreatic adenocarcinoma. Clin Cancer Res 17, 203-205, doi:10.1158/1078-0432. CCR-10- 2825 (2011).
5. Gatenby, R. A. & Gillies, R. J. Amicroenvironmental model of carcinogenesis. Nat Rev Cancer 8, 56-61, doi:10.1038/nrc2255 (2008).
6. Gillies, R. J., Robey, I. & Gatenby, R. A. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49 Suppl 2, 24S-42S, doi:10.2967/ jnumed.107.047258 (2008). (Pubitemid 351948035)
7. Wojtkowiak, J. W. et al. Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res 72, 3938-3947, doi: 10.1158/0008- 5472.CAN-11-3881 (2012).
8. De Sousa, E. M. F., Vermeulen, L., Fessler, E. & Medema, J. P. Cancer heterogeneity - a multifaceted view. EMBO Rep 14, 686-695, doi:10.1038/ embor.2013.92 (2013).
9. Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501, 338-345, doi:10.1038/nature12625 (2013).
10. Andreev, O. A., Engelman, D. M. & Reshetnyak, Y. K. pH-sensitive membrane peptides (pHLIPs) as a novel class of delivery agents. Mol Membr Biol 27, 341-352, doi:10.3109/09687688.2010.509285 (2010).
11. Hunt, J. F., Rath, P., Rothschild, K. J. & Engelman, D. M. Spontaneous, pHdependent membrane insertion of a transbilayer alpha-helix. Biochemistry 36, 15177-15192, doi:10.1021/bi970147b (1997). (Pubitemid 27527982)
12. Weerakkody, D. et al. Family of pH (low) insertion peptides for tumor targeting. Proc Natl Acad Sci U S A 110, 5834-5839, doi:10.1073/pnas.1303708110 (2013).
13. Reshetnyak, Y. K. et al. Measuring tumor aggressiveness and targeting metastatic lesions with fluorescent pHLIP. Mol Imaging Biol 13, 1146-1156, doi:10.1007/ s11307-010-0457-z (2011).
14. Vavere, A. L. et al. A novel technology for the imaging of acidic prostate tumors by positron emission tomography. Cancer Res 69, 4510-4516, doi:10.1158/0008- 5472.CAN-08-3781 (2009).
15. Macholl, S. et al. In vivo pH imaging with (99 m)Tc-pHLIP. Mol Imaging Biol 14, 725-734, doi:10.1007/s11307-012-0549-z (2012).
16. Andreev, O. A. et al. Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo. Proc Natl Acad Sci U S A 104, 7893-7898, doi: 10.1073/pnas.0702439104 (2007). (Pubitemid 47185847)
17. Daumar, P. et al. Efficient (18)F-Labeling of Large 37-Amino-Acid pHLIP Peptide Analogues and Their Biological Evaluation. Bioconjug Chem 23, 1557-1566, doi:10.1021/bc3000222 (2012).
18. Olive, K. P. & Tuveson, D. A. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 12, 5277-5287, doi:10.1158/ 1078-0432.CCR-06-0436 (2006). (Pubitemid 44497240)
19. Philip, B. et al. A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice. Gastroenterology 145, 1449-1458, doi:10.1053/j.gastro.2013.08.018 (2013).
20. Chiche, J., Brahimi-Horn, M. C. & Pouyssegur, J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med 14, 771-794, doi: 10.1111/j.1582-4934.2009.00994.x (2010).
21. Warburg, O.,Wind, F.&Negelein, E. The metabolism of tumors in the body. JGen Physiol 8, 519-530 (1927).
22. Newell, K., Franchi, A., Pouyssegur, J. & Tannock, I. Studies with glycolysisdeficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci U S A 90, 1127-1131 (1993). (Pubitemid 23053964)
23. Grillon, E. et al. The spatial organization of proton and lactate transport in a rat brain tumor. PLoS One 6, e17416, doi:10.1371/journal.pone. 0017416 (2011).
24. Rehncrona, S. Brain acidosis. Ann Emerg Med 14, 770-776, doi:S0196- 0644(85)80055-X (1985). (Pubitemid 15233320)
25. Xiong, Z. G., Pignataro, G., Li, M., Chang, S. Y. & Simon, R. P. Acid-sensing ion channels (ASICs) as pharmacological targets for neurodegenerative diseases. Curr Opin Pharmacol 8, 25-32, doi:10.1016/j.coph. 2007.09.001 (2008). (Pubitemid 351168687)
26. Swietach, P.,Vaughan-Jones, R. D.&Harris, A. L. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 26, 299-310, doi:10.1007/ s10555-007-9064-0 (2007). (Pubitemid 47101667)
27. Ihnatko, R. et al. Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int J Oncol 29, 1025-1033 (2006).
28. Hashim, A. I., Zhang, X., Wojtkowiak, J. W., Martinez, G. V. & Gillies, R. J. Imaging pH and metastasis. NMR Biomed 24, 582-591, doi:10.1002/nbm.1644 (2011).
29. Zhou, W. et al. Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J Proteome Res 11, 554-563, doi:10.1021/pr2009274 (2012).
30. Son, J. et al. Glutamine supports pancreatic cancer growth through a KRASregulated metabolic pathway. Nature 496, 101-105, doi:10.1038/nature12040 (2013).
31. Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670, doi:10.1016/j.cell.2012.01.058 (2012).
32. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15, 3243-3248, doi:10.1101/gad.943001 (2001). (Pubitemid 34008190)
33. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29, 418-425, doi:10.1038/ ng747 (2001). (Pubitemid 34326692)
34. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450, doi:S153561080300309X (2003). (Pubitemid 38050041)
35. Bardeesy, N. et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 103, 5947-5952, doi:10.1073/pnas.0601273103 (2006).
36. Ji, B. et al. Robust acinar cell transgene expression of CreErT via BAC recombineering. Genesis 46, 390-395, doi:10.1002/dvg.20411 (2008).
37. Arumugam, T., Ramachandran, V. & Logsdon, C. D. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 98, 1806-1818, doi:10.1093/jnci/djj498 (2006). (Pubitemid 46017932)